Peter Lynch fit · Growth at a reasonable price (GARP)
Is Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) a Peter Lynch Stock?
Some GARP characteristics, but growth or valuation is stretched.
72/100
BLikely Lynch stock
4/6 criteria passed
+10 sector-quality lift. Top-quintile within its sector on 5 of 5 quality metrics. Raw pillar score 62 → lifted to 72 before grade derivation.
Peter Lynch's Criteria, Applied to SUNPHARMA.NS
PEG ≤ 1.0
key3.54
EPS CAGR ≥ 15%
key10.6%
Revenue CAGR ≥ 10%
10.4%
Net margin > 0
19.7%
Manageable debt (D/E < 1)
0.1x
Positive free cash flow
Yes
How SUNPHARMA.NS Scores on Other Strategies
Live Financial Snapshot
Market cap
$4.33T
P/E (TTM)
37.6x
ROIC (TTM)
13.14%
Gross margin
80.17%
Other Peter Lynch fit reports
Frequently Asked Questions
What is SUNPHARMA.NS's Peter Lynch fit score?
SUNPHARMA.NS scores 72/100 on our Peter Lynch fit engine - grade B. Some GARP characteristics, but growth or valuation is stretched.
Does Peter Lynch actually own SUNPHARMA.NS?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends SUNPHARMA.NS.
How often is this score updated?
SUNPHARMA.NS's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Key terms in this analysis
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends SUNPHARMA.NS.